Evans John M.

CEO, DirectorBeam Therapeutics Inc. (BEAM) · full profile →Form 4 · filed Apr 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.1M
Net Open-Market Flow
-$1.1M
Transactions
7
5 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 31, 2026Sell(S)25K$22.76$569K987K
Mar 31, 2026Option exercise(M)25K$0.67$17K1.0M
Mar 31, 2026Grant(A)90K$01.1M
Mar 30, 2026Option exercise(M)25K$0.67$17K1.0M
Mar 30, 2026Sell(S)25K$22.37$559K987K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 31, 2026Option exercise(M)25K$019K
Mar 30, 2026Option exercise(M)25K$044K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-138348) within minutes of acceptance. Every field above traces to the original document. Verify it directly: